. Author manuscript; available in PMC: 2014 Jan 1.

Published in final edited form as: J Clin Immunol. 2012 Aug 19;33(1):14–21. doi: 10.1007/s10875-012-9749-1

Table V.

EVER2 deficiency compared to other deficiencies conferring susceptibility to EV-HPV infections

Deficiencies	EVER2	RHOH	MST1
Clinical phenotype	EV,	Persistent EV-HPV infections,	Persistent EV-HPV infections,
	High risk of NMSC	α-HPV cutaneous warts,	α-HPV cutaneous warts,
		MCV, HSV1 infections,	bronchitis, pneumonia,
		Burkitt lymphoma,	CMC, autoimmunity, growth retardation
		broncho-pulmonary disease
T-cell phenotype
Naive/ Memory	High memory CD4/CD8 (effector)	Very low naive/High memory	Lack of naive/High memory
Response to OKT3	Normal	impaired	impaired
Response to antigens	Variable	variable	variable
Response to mitogen (PHA)	Normal	impaired	moderately impaired
Tissue-homing subsets	High CLA⁺CD4⁺,	low CLA⁺,	ND
	High CCR10⁺ CD4⁺	Increase CLA⁺ naive
	Normal α E⁺,	Normal α E⁺,
	Normal α4⁺β7⁺	low α4β7⁺
Natural Killer cells phenotype	Normal ADCC	ND	ND
	Increased cytotoxic activity against K562 (P1, P3)

MCV molluscum contagosium virus; HSV1 Herpes simplex virus 1; CMC cutaneomucocutaneous candidiasis; ADCC antibody-dependent cell-mediated cytotoxicity; NMSC non-melanoma skin cancer; ND not done